Actively Recruiting
Evaluation of Lorlatinib Treatment Safety and Effectiveness in Untreated ALK-Positive Non-Small-Cell Lung Cancer Patients in a French Real-World Study
Led by Pfizer · Updated on 2026-10-23
90
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effectiveness and safety of lorlatinib in patients with untreated ALK-positive non-small-cell lung carcinoma NSCLC. This research is conducted in a French real-world setting and sponsored by Pfizer. The study aims to assess how lorlatinib performs as a treatment option for this specific type of lung cancer. Participants will receive lorlatinib as a single-agent oral treatment at a dose of 100 mg daily. The study is designed as a single-group trial where patients continuously take lorlatinib. The treatment and observation period includes assessments up to 25 months, during which various outcomes such as progression-free survival, overall survival, response rates, and treatment duration will be evaluated. During the study, participants will be monitored regularly with imaging tests like CT scans and brain MRIs before starting treatment. Researchers will track treatment adherence, symptom changes, adverse events, and resistance mechanisms. Patient-reported outcomes and quality of life questionnaires will be collected at multiple time points up to 48 months. Safety and effectiveness measures will guide the ongoing evaluation, with follow-up visits scheduled throughout the study period.
CONDITIONS
Brief Title
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here